Palomar Holdings, Inc. (NASDAQ:PLMR – Get Free Report) CFO T Christopher Uchida sold 783 shares of the firm’s stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $128.04, for a total value of $100,255.32. Following the completion of the sale, the chief financial officer directly owned 14,752 shares in the company, valued at $1,888,846.08. This trade represents a 5.04% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
T Christopher Uchida also recently made the following trade(s):
- On Saturday, January 31st, T Christopher Uchida sold 545 shares of Palomar stock. The stock was sold at an average price of $121.74, for a total transaction of $66,348.30.
- On Thursday, January 29th, T Christopher Uchida sold 1,326 shares of Palomar stock. The shares were sold at an average price of $122.04, for a total transaction of $161,825.04.
- On Thursday, January 29th, T Christopher Uchida sold 1,326 shares of Palomar stock. The stock was sold at an average price of $122.04, for a total transaction of $161,825.04.
- On Wednesday, January 28th, T Christopher Uchida sold 2,103 shares of Palomar stock. The shares were sold at an average price of $119.88, for a total transaction of $252,107.64.
Palomar Price Performance
Shares of Palomar stock opened at $120.61 on Monday. The company’s 50 day moving average price is $129.40 and its two-hundred day moving average price is $123.22. The firm has a market capitalization of $3.20 billion, a P/E ratio of 16.80 and a beta of 0.44. Palomar Holdings, Inc. has a fifty-two week low of $107.75 and a fifty-two week high of $175.85.
Analyst Ratings Changes
Several analysts have recently weighed in on PLMR shares. Keefe, Bruyette & Woods boosted their price target on Palomar from $170.00 to $171.00 and gave the stock an “outperform” rating in a report on Tuesday, January 6th. Wall Street Zen upgraded shares of Palomar from a “hold” rating to a “buy” rating in a research report on Saturday. Evercore began coverage on shares of Palomar in a report on Monday, February 9th. They set an “outperform” rating and a $150.00 target price on the stock. JPMorgan Chase & Co. raised their price target on shares of Palomar from $145.00 to $155.00 and gave the company an “overweight” rating in a research note on Wednesday, January 7th. Finally, Weiss Ratings upgraded shares of Palomar from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, January 14th. Seven research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Palomar presently has an average rating of “Buy” and an average price target of $162.17.
Get Our Latest Stock Analysis on Palomar
Institutional Inflows and Outflows
Hedge funds have recently added to or reduced their stakes in the company. Mercer Global Advisors Inc. ADV bought a new stake in shares of Palomar in the 4th quarter valued at $215,000. Summit Global Investments lifted its holdings in Palomar by 1.7% in the fourth quarter. Summit Global Investments now owns 4,646 shares of the company’s stock valued at $626,000 after buying an additional 79 shares during the period. Caitlin John LLC boosted its position in Palomar by 23,887.5% during the fourth quarter. Caitlin John LLC now owns 1,919 shares of the company’s stock valued at $259,000 after acquiring an additional 1,911 shares during the last quarter. State of Tennessee Department of Treasury grew its holdings in Palomar by 6.8% during the 4th quarter. State of Tennessee Department of Treasury now owns 15,275 shares of the company’s stock worth $1,888,000 after acquiring an additional 971 shares during the period. Finally, Mackenzie Financial Corp bought a new position in shares of Palomar in the 4th quarter worth about $854,000. Institutional investors own 90.25% of the company’s stock.
Palomar Company Profile
Palomar Holdings, Inc (NASDAQ: PLMR) is a specialty insurance holding company focused on providing medical stop-loss coverage and related administrative services to self-funded employer health plans in the United States. The firm operates through two primary business segments—Medical Stop-Loss and Specialty Program Management—to deliver tailored risk protection and comprehensive program administration.
In its Medical Stop-Loss segment, Palomar underwrites excess and aggregate stop-loss policies designed to shield self-insured employers from catastrophic medical claims that exceed pre-determined retention levels.
Recommended Stories
- Five stocks we like better than Palomar
- The gold chart Wall Street is terrified of…
- Buy this Gold Stock Before May 2026
- What a Former CIA Agent Knows About the Coming Collapse
- This $15 Stock Could Go Down as the #1 Stock of 2026
- “Fed Proof” Your Bank Account with THESE 4 Simple Steps
Receive News & Ratings for Palomar Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palomar and related companies with MarketBeat.com's FREE daily email newsletter.
